Login/Sign Up
Paclicad 260 Injection 43.4 ml
Paclicad 260 Injection 43.4 ml is used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. It contains ‘Paclitaxel’, which stops cell division and prevents certain cancer cell growth. Sometimes, Paclicad 260 Injection 43.4 ml may cause common side effects, such as nausea, vomiting, mild diarrhoea, and joint or muscle pain. It is not recommended for children below 18 years.
₹2275.5*
MRP ₹2775
18% off
₹2358.75*
MRP ₹2775
15% CB
₹416.25 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Whats That
Paclicad 260 Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer.
Paclicad 260 Injection 43.4 ml contains ‘Paclitaxel’, which works by stopping cell division and preventing the growth of certain cancer cells.
In some cases, Paclicad 260 Injection 43.4 ml may cause common side effects, such as nausea, vomiting, mild diarrhoea, and joint or muscle pain. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.
Consult your doctor if you are pregnant, breastfeeding, think you may be pregnant or are planning pregnancy. Paclicad 260 Injection 43.4 ml is not recommended for children below 18 years. Inform your doctor about your health condition and medications to rule out any side effects.
Paclicad 260 Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. It may also be used when other treatments have failed or in combination with other treatments. Paclicad 260 Injection 43.4 ml may also be indicated in patients with Kaposi’s sarcoma (cancer that develops from the cells that line lymph or blood vessels) associated with AIDS (Acquired Immuno-Deficiency Syndrome), where other treatments have not been effective. Paclicad 260 Injection 43.4 ml contains ‘Paclitaxel’, which works by preventing the growth of certain cancer cells.
Do not take Paclicad 260 Injection 43.4 ml if you are allergic to any of its components, if your white blood cell or platelet count is very low, if you have a serious uncontrolled infection, and Paclicad 260 Injection 43.4 ml has to be given for the treatment of Kaposi’s sarcoma (cancer that causes lesions in soft tissues), or if you have severe liver problems. Inform your doctor if you have heart disease, abnormal blood cell counts, irregular heartbeat, tingling, numbness, or burning sensation in fingers or toes, visual problems, if you are on radiation therapy, or if you have Kaposi’s sarcoma and have a sore or inflamed mouth. Also, inform your doctor if you are pregnant, breastfeeding, think you are pregnant or planning pregnancy.
Drug-Drug Interactions: Inform your doctor if you are taking antibiotics (rifampicin, erythromycin), anti-fungal (ketoconazole), anti-depressant (fluoxetine), anti-epileptic (carbamazepine, phenytoin), lipid regulating agent (gemfibrozil), antacid (cimetidine), medicines used to treat HIV/AIDS (ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine), anti-platelet (clopidogrel).
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Inform your doctor if you have a very low white blood cell or platelet count, a serious uncontrolled infection, or severe liver problems.
Breast cancer: It is a type of cancer that develops in the breast when the breast cells begin to grow abnormally. Symptoms of breast cancer include a lump in the breast or tissue thickening which feels different than the normal surrounding tissues, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin, and a lump or swelling under the arm.
Ovarian Cancer: Ovarian cancer occurs when abnormal cells grow and multiply in the ovaries and fallopian tubes. Signs and symptoms include pain, swelling, or a feeling of pressure in the pelvis or abdomen, frequent or sudden urge to urinate, feeling full or trouble eating, a lump in the pelvic area, gas, bloating, or constipation.
Non-small cell lung cancer: It is a disease in which cancer cells form in the tissues of the lungs. Smoking is the major risk factor for non-small cell lung cancer. Symptoms include a cough that does not go away and shortness of breath.
Alcohol
Consult your doctor
It is not known if alcohol interacts with this medicine. Please consult your doctor.
Pregnancy
Unsafe
Paclicad 260 Injection 43.4 ml must not be given during pregnancy unless clearly necessary, as it may cause birth defects. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Paclicad 260 Injection 43.4 ml.
Breast Feeding
Unsafe
Avoid breastfeeding whilst on treatment with Paclicad 260 Injection 43.4 ml. Do not restart breastfeeding until your doctor tells you it is safe to do so.
Driving
Caution
Paclicad 260 Injection 43.4 ml may cause dizziness, tiredness, or nausea. Drive or operate heavy machinery only if you are alert.
Liver
Caution
Do not use Paclicad 260 Injection 43.4 ml if you have severe liver problems. If you have a history of liver disease, inform your doctor before receiving Paclicad 260 Injection 43.4 ml.
Kidney
Consult your doctor
If you have a history of kidney diseases, inform your doctor before receiving Paclicad 260 Injection 43.4 ml. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Children
Unsafe
Paclicad 260 Injection 43.4 ml is not recommended for children below 18 years due to a lack of data on the safety and effectiveness.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes